Drug Database
Back to search

Poland· PL-100125023

Constella

A linaclotide product containing linaclotidum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.

ATC A06AX04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedConstellaATCA06AX04REGISTER NO.PL-100125023PACKS LISTED5CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about linaclotidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Linaclotide is registered in 14 of 19 countries.

Countries holding a registration under ATC A06AX04 (linaclotide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search linaclotide products by name

Linaclotide · ATC A06AX04

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of linaclotide costs, country by country.

Normalised to the WHO defined daily dose (0.29 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Linaclotide · price per daily dose (0.29 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$2.73
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Linaclotidum
Manufacturer
AbbVie Deutschland GmbH & Co. KG
Country
Poland (PL)
ATC code
A06AX04
ATC class
Linaclotide
Defined daily dose
0.29 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

  • gtin
    05909991026301
  • gtin
    05909991026332
  • gtin
    05016007206906
  • gtin
    05909991026349
  • gtin
    05909991026356

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

66 interactions on record for linaclotide.

Graded by severity as the source publishes them — 17 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check linaclotide against other medicinesHow interaction checks work

Linaclotide · interactions on record

66 records

  • 17 moderate
  • 49 minor

Most severe, free to view

  • IUP aus Plastik mit GestagenG02BA03moderate
  • Levonorgestrel and ethinylestradiolG03AA07moderate
  • Desogestrel and ethinylestradiolG03AA09moderate
  • Drospirenone and ethinylestradiolG03AA12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Linaclotide in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All linaclotide products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Constella
  • Iceland · Constella
  • Liechtenstein · Constella
  • Norway · Constella

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0c0dac48-099a-49ad-8eed-31337ed4956d
GET /v1/drugs/0c0dac48-099a-49ad-8eed-31337ed4956d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "290 mcg",
  "packaging": "05909991026301 ¦ Rp ¦ EU/1/12/801/001 ¦ 80775\n10 kaps.\n05909991026332 ¦ Rp ¦ EU/1/12/801/002 ¦ 80776\n28 kaps.\n¦ UR/Z/4c/169/25 - 05016007206906\n05909991026349 ¦ Rp ¦ Skasowane ¦ EU/1/12/801/003 ¦ 80777\n60 kaps.\n05909991026356 ¦ Rp ¦ EU/1/12/801/004 ¦ 80778\n90 kaps.\nRp ¦ EU/1/12/801/005 ¦ 119660\n112 kaps.",
  "substance": "Linaclotide 290 mcg",
  "common_name": "Linaclotidum",
  "pl_product_id": "100125023",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about linaclotide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console